KDOQI对美国KDIGO 2020慢性肾脏病糖尿病管理临床实践指南的解读
2020年10月,KDIGO发布了首部专门针对糖尿病合并慢性肾脏病(CKD)患者管理的临床实践指南。本解读呈现KDOQI糖尿病合并CKD工作组对该指南的独立专家观点,认为该指南在明确血糖目标和特定降糖药物使用方面迈出了重要一步。近期SGLT2抑制剂等进展填补了肾脏病学在糖尿病合并CKD患者管理中的长期空白,但简化实施和克服可及性障碍(尤其是费用)对确保所有患者获益至关重要。
要点
- KDIGO 2020指南是首部专门针对糖尿病合并CKD管理的临床实践指南。
- KDOQI工作组认为该指南在明确血糖目标和特定降糖药物使用方面迈出了重要一步。
- SGLT2抑制剂的多方面获益促进了肾脏科、心脏科、内分泌科和初级保健之间的互动。
核心结论
- KDOQI工作组认为KDIGO指南在明确血糖目标和糖尿病合并CKD中特定降糖药物使用方面迈出了重要一步。
- SGLT2抑制剂的多方面获益促进了多学科互动,凸显了创新多学科护理方法的必要性。
- 简化实施和克服可及性障碍(尤其是费用)对确保所有患者获益至关重要。
研究设计与样本
- 本解读由美国国家肾脏基金会召集的KDOQI糖尿病合并CKD工作组撰写,旨在对KDIGO 2020指南提供独立专家观点。
主要发现
- 近期SGLT2抑制剂等进展填补了肾脏病学在糖尿病合并CKD患者管理中的长期空白。
- SGLT2抑制剂的多方面获益促进了肾脏科、心脏科、内分泌科和初级保健之间的互动。
- 目前有更多干预措施可延缓糖尿病合并肾脏病患者的肾病进展并预防或延迟肾衰竭。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In October 2020, KDIGO (Kidney Disease: Improving Global Outcomes) published its first clinical practice guideline directed specifically to the care of patients with diabetes and chronic kidney disease (CKD). This commentary presents the views of the KDOQI (Kidney Disease Outcomes Quality Initiative) work group for diabetes in CKD, convened by the National Kidney Foundation to provide an independent expert perspective on the new guideline. The KDOQI work group believes that the KDIGO guideline takes a major step forward in clarifying glycemic targets and use of specific antihyperglycemic agents in diabetes and CKD. The purpose of this commentary is to carry forward the conversation regarding optimization of care for patients with diabetes and CKD. Recent developments for prevention of CKD progression and cardiovascular events in people with diabetes and CKD, particularly related to sodium/glucose cotransporter 2 (SGLT2) inhibitors, have filled a longstanding gap in nephrology's approach to the care of persons with diabetes and CKD. The multifaceted benefits of SGLT2 inhibitors have facilitated interactions between nephrology, cardiology, endocrinology, and primary care, underscoring the need for innovative approaches to multidisciplinary care in these patients. We now have more interventions to slow kidney disease progression and prevent or delay kidney failure in patients with diabetes and kidney disease, but methods to streamline their implementation and overcome barriers in access to care, particularly cost, are essential to ensuring all patients may benefit.
引用
- Mottl AK, Alicic R, Argyropoulos C, et al. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis. 2022. PMID: 35144840. doi:10.1053/j.ajkd.2021.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。